The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study ...

An experimental vaccine for HIV is set to be tried on humans in 2019.

Immunization saves millions of lives and is widely recognized as one of the world’s most successful and cost-effective health interventions. Yet, there are more than 19 million unvaccinated or under-vaccinated children in the world, putting them at serious risk of these potentially fatal diseases. Of ...

Therapies to prevent infection are advancing in a crowded field.

The type of vaccine administered and the activation of the body's own immune cells influence the vaccine protection.

Influenza vaccination is recommended for HIV-infected patients, but limited data about vaccination rates are available. The aim of this study was to evaluate the coverage of and predictors for influenza vaccination among HIV-positive patients.

Elicitation of a Key Precursor for Broadly Neutralizing Antibody for the HIV CD4 Binding Site